All In Biotech

Drug Trial Radar · NCT03915184

Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)

Open Label, Multi-center, Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Autologous CAR BCMA T Cells (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)

Last checked: Nov 19, 2026Latest source record: Dec 19, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

105

Planned (sponsor's estimate)

Start

Sep 25, 2019

Primary completion

Dec 31, 2024

Study completion Dec 31, 2034

Sponsor

Lead sponsor
CARsgen Therapeutics Co., Ltd.Industry
Sponsor type
Industry
First posted
Apr 16, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 79 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A phase 1b/2, open label, multi-center, Clinical Study of Chimeric Antigen Receptor T Cells targeting BCMA in patients with relapsed and or refractory multiple myeloma.

Conditions

  • Multiple Myeloma

Interventions

  • zevor-celBiological

    A single autologous chimeric antigen receptor-B-cell maturation antigen (CAR-BCMA T cell) infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment Related adverse events (AEs)Time frame: Day 1 - Month 60
  2. Identification of Maximum Tolerated Dose (MTD)Time frame: Day 1 - Month 60
  3. Objective response rateTime frame: Day 1 - Month 60

Locations

13 sites in 2 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Hospital

    Phoenix, Arizona

  • UCSF

    San Francisco, California

  • Colorado Blood Cancer Institute

    Denver, Colorado

  • Moffitt Cancer Center

    Tampa, Florida

  • Dana Farber Cancer Center

    Boston, Massachusetts

  • Mayo

    Rochester, Minnesota

  • TriStar CMC

    Nashville, Tennessee

  • UT Southwestern Medical Center

    Dallas, Texas

  • MD Anderson

    Houston, Texas

  • Methodist Hosptial

    Houston, Texas

  • Huntsman Cancer Center

    Salt Lake City, Utah

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

  • Princess Margaret Hospital

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.